Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elaine M Hylek

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
JAMA Cardiology|October 19, 2022
Catheter-Directed Treatment of Submassive Pulmonary Embolism-A Cautious Step Closer?Elaine M Hylek
Seminars in Thrombosis and Hemostasis|February 12, 2013
Anticoagulation therapy for atrial fibrillationElaine M Hylek
Journal of Thrombosis and Thrombolysis|March 5, 2013
Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvementElaine M Hylek
Journal of Thrombosis and Thrombolysis|February 5, 2004
Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) studyElaine M Hylek
Thrombosis and Haemostasis|July 10, 2008
Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillationElaine M Hylek
Thrombosis and Haemostasis|October 7, 2004
Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycleElaine M Hylek
Seminars in Thrombosis and Hemostasis|September 30, 2009
Antithrombotic prophylaxis in elderly patients with atrial fibrillationElaine M Hylek
The New England Journal of Medicine|September 3, 2013
Dabigatran and mechanical heart valves--not as easy as we hopedElaine M Hylek
The New England Journal of Medicine|December 24, 2010
Therapeutic potential of oral factor Xa inhibitorsElaine M Hylek
Heart (British Cardiac Society)|August 10, 2016
Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviourElaine M Hylek
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
JAMA Cardiology|October 19, 2022
Catheter-Directed Treatment of Submassive Pulmonary Embolism-A Cautious Step Closer?Elaine M Hylek
Seminars in Thrombosis and Hemostasis|February 12, 2013
Anticoagulation therapy for atrial fibrillationElaine M Hylek
Journal of Thrombosis and Thrombolysis|March 5, 2013
Vitamin K antagonists and time in the therapeutic range: implications, challenges, and strategies for improvementElaine M Hylek
Journal of Thrombosis and Thrombolysis|February 5, 2004
Trends in anticoagulation management across community-based practices in the United States: the Anticoagulation Consortium to Improve Outcomes Nationally (ACTION) studyElaine M Hylek
Thrombosis and Haemostasis|July 10, 2008
Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillationElaine M Hylek
Thrombosis and Haemostasis|October 7, 2004
Paracetamol (acetaminophen) and warfarin interaction: unraveling the pivotal role of the vitamin K cycleElaine M Hylek
Seminars in Thrombosis and Hemostasis|September 30, 2009
Antithrombotic prophylaxis in elderly patients with atrial fibrillationElaine M Hylek
The New England Journal of Medicine|September 3, 2013
Dabigatran and mechanical heart valves--not as easy as we hopedElaine M Hylek
The New England Journal of Medicine|December 24, 2010
Therapeutic potential of oral factor Xa inhibitorsElaine M Hylek
Heart (British Cardiac Society)|August 10, 2016
Antithrombotic drug use: scientific breakthroughs, biological limits and physician behaviourElaine M Hylek
Pageof 21